Research programme: CNS biotherapeutics - Axial Biotherapeutics/California Institute of Technology

Drug Profile

Research programme: CNS biotherapeutics - Axial Biotherapeutics/California Institute of Technology

Alternative Names: AB 2004

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator California Institute of Technology/CalTech
  • Developer Axial Biotherapeutics; Parkinsons Institute and Clinical Center
  • Class Antiparkinsonians; Bacteria; Neuroprotectants; Probiotics; Small molecules
  • Mechanism of Action Microbiome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autistic disorder; Parkinson's disease

Most Recent Events

  • 26 Jun 2018 QC Feedback incorporated
  • 22 Jun 2018 Axial Biotherapeutics enters into an R&D agreement with Parkinson’s Institute and Clinical Center.
  • 22 Jun 2018 Preclinical trials in Autistic disorder in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top